Streetbeat News

Products Services

ADMA

ADMA Biologics has received FDA approval for extended room temperature storage conditions for its products ASCENIV and BIVIGAM. This approval applies to all existing and future production lots of these products in the commercial supply chain.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:01 am

CAL

Caleres' brand Sam Edelman has launched its Spring/Summer 2024 campaign featuring Kylie Jenner. The collection is now available on SamEdelman.com and in retail stores globally.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:50 am

WPRT

Westport Fuel Systems Inc. has signed an investment agreement to establish a joint venture with Volvo Group, as previously announced. This strategic partnership aims to enhance the development and commercialization of Westport's high-pressure direct injection (HPDI) technology for hydrogen applications in Volvo Group's products.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:37 am

FA

First Advantage has launched RightID, a next-generation tool utilizing generative AI and machine learning to identify errors or fraudulent information in job applicant identities during the pre-hire process. This innovation aims to enhance the accuracy and efficiency of the hiring process by detecting potential fraud in real-time.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:02 am

MDT

Medtronic shared new clinical and real-world evidence on Saturday about the MiniMed 780G system from early users in the United States, indicating that the system sustains strong global performance and exceeds international targets for diabetes management.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:40 am

INCY

Incyte announced positive results from a Phase 2 study of Povorcitinib (INCB54707) for treating prurigo nodularis, meeting its primary endpoint with significant improvement in itch compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:36 am

INCY

Incyte announced positive results from a Phase 2 study of Ruxolitinib Cream (Opzelura) in treating Hidradenitis Suppurativa, meeting its primary endpoint with a significant reduction in abscess and inflammatory nodule count versus vehicle control.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:34 am

AMGN

Amgen announced new 52-week results from the Phase 3 SPROUT study of Otezla (Apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis on Saturday.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:13 am

ARQT

Arcutis Biotherapeutics released new data from its INTEGUMENT-PED Phase 3 study of Roflumilast Cream for treating children aged 2 to 5 with mild to moderate atopic dermatitis. The results showed significant improvements across multiple efficacy endpoints and at all timepoints.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:11 am

LLY

Eli Lilly announced positive results from a study of Lebrikizumab in individuals with skin of color suffering from moderate-to-severe atopic dermatitis, showing significant improvement in skin clearance and itch relief.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 9:08 am